header logo image


Page 1,082«..1020..1,0811,0821,0831,084..1,0901,100..»

Cure For Cat campaign launches a second time to save Cat Davis’ life – KXLY Spokane

March 3rd, 2017 2:45 am

SPOKANE, Wash. - Spokane rallied to save her life once before, and now she needs the community's help again.

The "Cure For Cat" campaign helped Cat Davis pay for a transplant that doctors thought would save her life, but she relapsed, and now needs another transplant.

"My gut feeling is that if this doesn't happen, she might have a year, at best," said Sally Davis, Cat's mother.

Living with scleroderma means everyday is a fight for survival for Cat.

"Right now I'm alive, but I'm not living," she said. "I want more for myself and I want more for everyone else who struggles with scleroderma."

The 29-year-old has spent most of her adult life raising awareness for the disease, which hardens the skin and internal organs. It all began with a diagnosis, which sparked the Cure For Cat campaign.

Four years ago the Spokane community raised hundreds of thousands of dollars for a stem cell transplant that helped Cat keep the disease at bay. Until it didn't.

"We had such high hopes for the first transplant and now that she's relapsed from them, we have to face the fact that we have to do this all over again," said Sally Davis.

Cat must now fight again, this time going through a transplant using her brother's stem cells. The chance of death for Cat this time around is somewhere near 50%.

"I want to fight for those who have died and because of everything that's happened to me over the last few years because of Scleroderma, I'm ready to take that risk," Davis said.

She's launching round two of the Cure For Cat campaign. It began with a video release Wednesday. She hopes the second time through this, she can provide hope for everyone who fights each day to survive. Cat would be the first person with scleroderma to receive this second groundbreaking transplant.

"Yesterday, on Wednesday, we launched the second Cure For Cat campaign and it's been awesome. And the main thing I want people to understand is it's so much different than the first campaign," she said.

On March 18th, Cat will hold a benefit concert at the Service Station as a kickoff fundraiser. She says there are also some events in the works that will be announced soon.

"Spokane is an incredible community and we can do this together and I know, in the end, together we are better and we're going to make a difference," she said.

For more information about events and how you can donate, visit cureforcat.com.

More:
Cure For Cat campaign launches a second time to save Cat Davis' life - KXLY Spokane

Read More...

Philanthropy vs. Blindness: What’s the Latest? Inside Philanthropy – Inside Philanthropy

March 3rd, 2017 2:45 am

If ever there were a problem that might seem tailor-made for philanthropy, it's fighting blindness. Losing sight is a horrifying fate for anyone to contemplate, and it's not surprising that blindness has motivated some deep-pocketed donors for at least a century. Over the past few decades, significant gains have been made in this area. In the United States, for example, the Foundation Fighting Blindnessco-founded by venture capitalist George Gund in 1971has raised over $600 million to fund research advances to prevent and cure retinal degenerative diseases that affect more than 10 million Americans. Worldwide, a range of efforts have sought to bring poor countries affordable cataract surgery. Cataracts are the main cause of blindness for half of the 40 million or so people who cannot see. Millions of people can see today because of these efforts.

This fight would seem eminently winnable, given that the World Health Organization estimates that 80 percent of blindness is avoidable, meaning it can be either prevented or reversed. Spurred on by that hopeful fact, the WHO galvanized a plan in 1999 called Vision 2020,a global initiative to prevent avoidable blindness, with a coalition that includes a number of foundations and top nonprofits.That milestone is now just three years away, and much work remains.

As usual, one key obstacle to faster progress has been funding. Never mind that the world's 2,500 billionaires now have assets of around $7.6 trillionthere's just never enough private or public money to fight blindness. Today's wealthy spend a fortune on luxuries even as millions of their fellow human beings cannot see. As a practical matter, reducing blindness has to compete with a bunch of other global health priorities, starting with diseases that actually kill people, like malaria and HIV/AIDS.

In addition, there aren't nearly as many major funders focused on preventing blindness as you might think. Very few of the largest U.S. foundations have made this a priority.

The Gates Foundation has patched in and out of this issue over the past 18 years, spending tens of millions fighting neglected tropical diseases that cause blindness, including large grants in the past to the Carter Center, the Task Force for Global Health, and Johns Hopkins University. But blindness hasn't been a big priority lately, at least compared to the foundation's investments in other areas.

Recently, the MacArthur Foundation announced that two of its eight semi-finalists for a special $100 million grant were organizations fighting blindness: Himalayan Cataract and the Carter Center. The fact these two made it into the top tier out of 2,000 proposals underscores the potential for big new money to make a huge impact (which is the goal of Mac's 100&Change competition).

While MacArthur's entry into the blindness space could be a game-changer, the Conrad N. Hilton Foundation stands out as one of the steadier big funders here. In particular, it's worked tirelessly to eliminate trachoma, a major cause of blindness. Trachoma is a result of repeated chlamydia trachomatis infections in the eyes. The infection, which typically starts in infancy or childhood, causes the eyelid to turn inward, resulting in corneal scarring caused by the eyelashes rubbing on the eyeball. Trachoma is incredibly painful, and if left untreated, leads to irreversible blindness. The debilitating disease is endemic in some of the poorest countries in the world.

Hilton uses the World Health Organizations (WHO) SAFE strategy (surgery, antibiotics, facial cleanliness, and environmental improvement) approach to eliminating blinding trachoma in Mali, Niger, and Tanzania. The foundation has played a crucial role in eliminating the disease in Ghana, which achieved its elimination targets in 2014. While this is a major success, Hilton isnt celebrating just yet. The foundation still has blinding trachoma in its sights and just awarded millions in grants to eliminate the disease.

Related: Researching Blindness Treatments? Conrad N. Hilton Foundation is on Your Side

Hilton made a total of $11.725 million in grants to three organizations that know more than a little bit about trachoma and avoidable blindness.

At just under $6 million, Helen Keller International received the largest award in this round. Established over 100 years ago, Helen Keller International has been on the front lines of the global trachoma battle since the 1950s, and has over 120 programs across Africa and Asia. Using the WHO's SAFE strategy as well, Helen Keller administered more than 80.5 million integrated neglected tropical disease (NTD) treatments in six African countries in 2016.

Coming in a close second behind Helen Keller International, the Carter Center received a $5.1 million grant from Hilton. The Carter Center has been a leader for over 30 years in the war against NTDs such as guinea worm, river blindness and trachoma. Since 1999, Carter has implemented the SAFE strategy in Mali and Niger. The Carter Center has facilitated thousands of surgeries and administered more than 500 million doses of antibiotics through its mass drug administration programs. Carter has also backed the construction of nearly 220,000 latrines in Mali and Niger. Better water, sanitation, and hygiene plays a critical role in preventing the spread of trachoma.

The final grant in this round was awarded to Sightsavers, which received $650,000. Sightsavers is a U.K.-based organization that has been working to eliminate avoidable blindness for six decades in over 30 countries around the world. Over the years, the group has supported more than 575 million treatments for blinding and potentially blinding conditions, and backed over 8 million surgeries to restore sight. Caroline Harper, CEO of Sightsavers, called Hiltons donation vital to meeting the WHO target for eliminating blinding trachoma by 2020.

Helen Keller International and the Carter Center are using the Hilton grants for trachoma prevention and elimination programs in Mali and Niger. Sightsavers is using its donation from Hilton to back its work in Mali. Both countries are within reach of their trachoma elimination targets.

Related: Where Have Hiltons Global Grants Been Going Lately?

The Hilton Foundations $11.725 million in grants certainly provides a nice boost toward eliminating trachoma in Mali and Niger, and the leveraging power of those funds could help both countries reach the elimination finish line. Hiltons latest trachoma grants require a dollar-for-dollar match by 2020 from each organization. Meaning, the foundation is effectively mounting a three-year, $23.45 million trachoma eradication campaign.

Read this article:
Philanthropy vs. Blindness: What's the Latest? Inside Philanthropy - Inside Philanthropy

Read More...

Association’s Name Change Focuses on Sight, Not Blindness – Associations Now

March 3rd, 2017 2:45 am

The New Hampshire Association for the Blind doesnt want to limit its mission because of its name.

As a result, this week the 105-year-old organization announced that it is changing its name to Future in Sight, which the group says better reflects its goal and overall duties within the state.

In an interview with New Hampshire Public Radio, Future in Sight President and CEO David Morgan noted that 93 percent of the people the organization serves have some form of sight loss but arent blind.

From the interview:

Up until recently, we never served babies. We served seniors, but not outside their home. And more and more, were discovering there are some 30,000 New Hampshire residents with profound sight loss, and we only served about 1,100 last year. So theres certainly a compelling need out there thats left unfulfilled. And frankly, the word blind in our name inhibited a lot of conversations, particularly in doctors offices and between doctors and their patients.

The latter situation proved a significant problem for the organization, according to Morgan, who told the Concord Monitor that the group had expanded its mission in recent years, partly because of changes with the states offerings. As a result, the association has received more referrals from doctors.

But these referrals created problems because members of the public were thrown off by the name.

The new name already has had an important impact on these conversations, Morgan stated.

As we stopped using the word blind, what we did was create new conversation around the word sight and the use of whats left for residual sight for both school-age kids and adults, he explained in his New Hampshire Public Radio interview.

In a blog post, Morgan added that the group is also expanding its mission to bordering states around New Hampshire.

Share this article

Link:
Association's Name Change Focuses on Sight, Not Blindness - Associations Now

Read More...

Run color blindness tests on your websites – gHacks Tech News – Ghacks Technology News

March 3rd, 2017 2:45 am

Color blindness affects a large percentage of the population. Studies have shown that up to 8% of males and 0.5% of females of Northern European heritage are affected by red-green color blindness for instance. The ability to distinguish between colors gets worse with age as well.

As a webmaster, you may want to make sure that your site is accessible to visitors with color blindness, or difficulties distinguishing certain color patterns.

This gives those users a better experience on your site, and may prevent part of them from insta-closing the site when they run into accessibility issues.

Probably the best way of checking your websites quickly when it comes to accessibility for color blind visitors is to use a browser extension. Some sites and services may require more than that, but the extensions should be fine for the majority of webmasters out there.

RGBlind is a simple extension. It adds an icon to the main Firefox (or Chrome) toolbar on installation that you can click on to switch between two color blindness simulation modes.

You may switch to test Protanopia or Deuteranopia, and will notice that the color scheme of the site you are on changes immediately once you make a selection. The difference between the two forms is that in protanopia, the red retinal photoreceptors are missing, whereas in deuteranopia, it is the green photoreceptors that are missing.

Basically, what the test does is simulate color blindness, so that you can see how a color blind person would see the website.

Dalton for Chrome adds tests for eight different types of color blindness to the browser. Simple navigate to the website that you want to check for accesibility, click on the extension icon, and select one of the available types (Achromatomaly, Achromatopsia, Tritanomaly, Tritanopia, Deuteranomaly, Deuteranopia, Protanomaly, Protanopia)

The extension pains the colors of the site accordingly, so that you can verify what works, and what does not.

You need to click on each type separately to test them all. An option to rotate through all types automatically would be useful, but is not provided.

Another browser extension for Google Chrome that you may use to test a site#s accessibility for the color blind.

It works almost identical to Dalton above: click on the icon, select one of the available types, and watch as the site's color scheme gets modified accordingly by the extension. Supports the same eight types as Dalton.

Colorblind test extensions for Firefox and Chrome are helpful to webmasters and designers, as it allows them to test a site's or design's accessibility. The extensions are easy to use, and it should not take longer than a couple of minutes to run initial tests to find out how well, or not, the site displays for visitors affected by the various types of color blindness.

Now You: are you color blind? Are there many sites out there that don't show up correctly for you?

Summary

Article Name

Run color blindness tests on your websites

Description

Find out how to run color blindness tests on your websites or designs, to make sure they are accessible by people affected by the various types of color blindness.

Author

Martin Brinkmann

Publisher

Ghacks Technology News

Logo

You are here: Home > Development > Run color blindness tests on your websites

Read the original:
Run color blindness tests on your websites - gHacks Tech News - Ghacks Technology News

Read More...

Why Puma Biotechnology Inc. Got Hammered Today – Madison.com

March 3rd, 2017 2:44 am

What happened

Puma Biotechnology (NASDAQ: PBYI) ended the day down 13.8% after Roche (NASDAQOTH: RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed "Aphinity."

Image source: Getty Images.

In Roche's trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy, and then took Perjeta and Herceptin, or just Herceptin, for an additional year. Roche didn't release the full data from the clinical trial, but it did say the triple combination reduced the risk of recurrence of invasive disease or death compared to Herceptin and chemotherapy alone.

The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.

Without any data, doctors will likely wonder whether neratinib helps patients that have received Herceptin and Perjeta. And the relapse rate for patients on the current standard of care is already quite low; if adding Perjeta decreases it further, doctors and their patients may decide taking another drug after that isn't worth it, especially given neratinib's side-effect profile.

Investors will have to wait for the full data from Aphinity -- perhaps at the American Society of Clinical Oncology meeting in June -- to know how much better Herceptin plus Perjeta is than Herceptin alone, and how that might affect neratinib's sales, assuming it's approved later this year.

10 stocks we like better than Puma Biotechnology

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Puma Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.

*Stock Advisor returns as of February 6, 2017

Visit link:
Why Puma Biotechnology Inc. Got Hammered Today - Madison.com

Read More...

When Celebrity And Science Collide: Hollywood And The Anti … – Genetic Literacy Project

March 3rd, 2017 2:44 am

Julie Kelly, cooking instructor, food writer, blogger and a Mom who lives in the Chicago area. In 2015, she got passionate about GMOs. Kelly is a contributing writer to the Wall Street Journal, National Review, Huffington Post, The Hill and other media outlets.| March 2, 2017

HIGHLIGHTS:

Hollywood is in our homes daily,often spreading misconceptions about science, and GE crops in particular Gary Hirshberg, founder of Stonyfield Organic and Just Label It, is the key celebrity organizer Gwyneth Paltrow has emerged as the face of celebrity moms who question the safety of GE foods Mark Ruffalo questions GE foods but also rejects biotechnological solutions beyond food, such as the gene-edited mosquito that could curtail the Zika virus Celebrity misinformation campaigns have filled a void created by the agricultural and food industries, which have been reticent to defend the science of biotechnology While the Internet and social media are valuable tools for disseminating information about complicated subjects like science and agriculture, it has also given rise to a modern-day monster: the expert celebrity From movie stars to television chefs, a cadre of self-promoting yet often ill-informed celebrities are influencing the public discussion about topics way beyond their expertise, particularly consequential issueslike vaccines and biotechnology

The explosive growth of cable television and more recently of the Internet has led to a celebrication of everyday lifeHollywood has invaded our homes in an oddly intimate way. Celebrities have long weighed in on public issues, which is okay if the issue is what clothes to wear next season, but science is different: it actually can impact peoples lives.

If Big Bang star Mayim Bialik talks about Zikas impact on the brain, we might be interested because she has a PhD in neurosurgeryshe has genuine credentials. But science-educated stars are few and far between. For example, campaigns led by Robert Kennedy, Jr., reality TV star Jenny McCarthy and her former husband Jim Carrey and flip comments by Bill Maher have convinced a lot of credulous fans to forgo getting their kids vaccinated the lowest vaccination rates in the country are in the swanky Hollywood suburban playgrounds. And thats just one of many misguided celebrity-driven campaigns.

Celebrities may have any number of motives for injecting themselves into the middle of debates over controversial, scientific issues. Ego, for example. Its a way to get publicity for themselves (McCarthy is more known now for her anti-vaccine activism than for her acting.) And as we know, stars are eager to follow the cause du jour. It is science-as-fashion.

While some people wisely ignore celebrity advice, their ill-informed and selectively ignorant comments can sway public opinion in destructive ways. Thats whats happening in the ongoing debate over our food and farming systems. In the last few years, movies such as Consumed and GMO OMG have fueled misperceptions about genetic engineering. And celebrity chefs such as Tom Colicchio have joined the fray, partnering with other anti-GMO chefs in a Facebook page, Chefs Against GMOs, and making appeals in Washington and on TV shows. But Hollywood is where anti-GMO groups draw their most visible campaigners.

A slew of Hollywood celebrities, have lent their names to one anti-GMO or pro-labeling campaign or another, among them a fading generation of actors and musicians: Morgan Freeman, Paul McCartney, Dave Mathews, Danny DeVito, Woody Harrelson and Neil Young, to name just a few. But there are some younger faces who have lobbied hard against modern agriculture, mostly B-list actresses, with Gwyneth Paltrow the most prominent. They rail against GMOs in an effort to persuade consumers our food system is hopelessly broken, and that crop biotechnology is scary, unnatural and part of a corporate conspiracy to control the worlds food supply. Its easily dismissible nonsense to those who know the consensus science, but their distortions have consequences outside of clickbait headlines.

Paltrow has emerged as the face of the anti-GMO movement over the last few years. Its unclear exactly how or why she decided to take up this cause except that she has worked closely with one of the most powerful figures in the organic movement, Gary Hirshberg, founder of Stonyfield Organic, who also started Just Label It, which has campaigned for mandatory labels. Just Label it and the organic industry in general have spent hundreds of millions of dollars in recent years to demonize conventional agriculture and mislead consumers into thinking organic food is healthier, safer and more nutritious than conventional food.

Although state-of-the-art meta studies conclude there are no meaningful differences, and some research shows organic farming is more stressful on the environment than farming using advanced technology including genetically engineered crops, organic companies peddle that narrative in hopes of driving consumers toward their pricier products. As the self-appointed priestess of all that is healthy and good in the world, Paltrow promotes organic food, which is by definition non-GMO.

Hirshberg has fueled and funded anti-GMO advocacy under the guise of promoting mandatory GMO labels. He has organized several anti-GMO groups, and has used celebrities like Paltrow to push his agenda. At his invitation, Paltrow was featured at a press conference on Capitol Hill in August 2015 to voice her support for mandatory GMO labeling. A bill the organic industry opposed had just passed in the House, and Paltrow wanted to use her powers of persuasion to stop the bill from advancing in the Senate:

Im not here as an expert, Im here as a mom who honestly believes I have the right to know whats in the food I feed my family. And we dont even know, the science is still inconclusive about GMOs, there are arguments they could possibly be harmful and there are arguments that they could be incredibly beneficial. But at this point, we just dont know.

The presser echoed widely on social media, but most disturbingly, her comments were reported uncritically by major media sites, giving her credibility on an issue she did not deserve.

Here is where Paltrow is wrong. We do know that GMOs are safe. They hold tremendous potential and promise to alleviate global hunger now and into the future as food demands are expected to nearly double by 2050.Nearly every major independent scientific organization and governmental agency in the world, including most recently the National Academies of Sciences, Engineering and Medicine (NAS), have affirmed that genetically engineered crops and food are just as healthy and environmentally safe as other conventionally grown foods, including organic. American farmers have been using genetically modified seeds for 20 years and most of the corn, soy, cotton and sugarbeets grown are from those seeds. This has cut down on the use of pesticides (since some of those crops have been developed to include natural pesticides already used by organic farmers), which has reduced crop losses and increased yield, a huge boon to both farmers and consumers.

In its analysis of the GMO controversy, the NAS also noted several problems with mandatory labeling, such as higher costs to consumers and the probability that companies might eliminate genetically engineered ingredients in order to avoid labels. The report also outlined several crops that can only be achieved through genetic engineering that boost nutrients, withstand climate challenges and resist crop diseases. Promising new crops in the pipeline include nutritionally enhanced rice and bananas and disease-resistant cassava, a plant that hundreds of millions depend on every day. So, its galling for an ultra-rich celebrity to spread falsehoods about a technology that can feed and fortify the diets of hundreds of millions of poor people around the world.

That wasnt the last we heard from Paltrow. In April 2016, she made a brief cameo in a video sponsored by Just Label It (with Hirshberg taking a star turn) entitled GMO Transparency in the Real World. A harried mother attempts to use her smart phone to scan a QR code on a can of soup to see if the soup contains GMOs (QR codes are anathema to the pro-GMO labeling crowd). As she stumbles to use her smart phone, and her kids smash a watermelon in the aisle, a fresh-faced Paltrow appears from the dairy aisle, asking the distraught mom if she has a scanner on her smart phone that she could use.

Paltrow isnt the only actress to play the Im not an activist, Im a mom card. Around Mothers Day 2015, several B-list mom-actresses appeared in a Moms Against GMOs video produced by another Hirshberg group to talk about GMOs, including Sarah Michelle Gellar, The Talks Sarah Gilbert, UnREALs Constance Zimmer, Once Upon a Times Ginnifer Goodwin, Furious 7s Jordana Brewster, The Biggest Losers Jillian Michaels, Mariel Hemingway and Sharon Osbourne. They pledged to protect their little ones from the dangers of GMOs: This Mothers Day, give moms the right to know whats in the food we feed our kids. Tell the FDA to require GMO labeling.

These actresses are now part of a coordinated, calculated attack on American agriculture and an attempt to stop millions of farmers from using technological tools necessary for their livelihood and Americas food security. They are part of a destructive campaign to hurt American farmers and our overall agricultural and food system.

Since a bill requiring mandatory GMO labels passed Congress and was signed into law by President Obama in August 2016, the GMO labeling groups have been more forthcoming about their true motives. Anti-GMO activist and Institute for Responsible Technology founder Jeffrey Smith, who makes regular appearances on Dr. Oz and other celebrity-type shows, acknowledged their real agenda:

Labeling GMOs was never the end goal for us. It was a tactic. Labels make it easier for shoppers to make healthier non-GMO choices. When enough people avoid GMOs, food companies rush to eliminate them. Labeling can speed up that tipping pointbut only if consumers are motivated to use labels to avoid GMOs.

Some celebrities brazenly profit by spreading misinformation about biotechnology. Jessica Alba parlayed her fame into selling organic, non-GMO products as part owner of The Honest Company. She boasts about the naturality of her products, from organic baby formulameticulously blended using non-GMO, naturally derived, organicto organic tampons to non-GMO lip balm. Many items brandish a non-GMO label. Alba explains her healthy eating habits as trying to have the least amount of GMOs and pesticides you have energy, arent starving and dont have to count calories.

Actor and progressive environmental activist Mark Ruffalo, who does not have a college education, has embraced any number of controversial causes, from fracking to GMOs, where the science is contested. He became a rock star in the anti-GMO community, even confronting Monsanto CEO Hugh Grant in a CBS green room rant before a joint TV appearance and later bragging about it.

You are wrong, he lectured Grant. You are engaged in monopolizing food. You are poisoning people. You are killing small farms. You are killing bees. What you are doing is dead wrong. Its the horrible stuff you guys do that makes you and your company horrible. People like you and your company are horrible because you are horrible.

He has more than 2 million followers on Twitterthats scary. His obsession to demonize genetic engineering took a bizarre turn earlier this year when he started tweeting that the Zika virus was caused by a chemical manufactured by an obscure Japanese company that has a research pact with Monsanto, the bete noire of anti-GMO activists. By doing so, he deflects attention from what experts now say is the only feasible solution to containing Zikathe release of genetically engineered sterile mosquitoes to drive out the poison-carrying ones.

Chef Attack

Many celebrity chefs have taken up the anti-GMO crusade, apparently believing their ability to run a restaurant or cook on television gives them special insight into how food is grown on a farm. Tom Colicchio, the star of Bravos Top Chef program, gathered signatures of more than 4,000 chefs on a petition he delivered to Capitol Hill in March 2016 demanding mandatory GMO labels and rejecting a Senate bill that would have made the labels voluntary.

He claims he only supports the right to know. But his twitter feed is filled with anti-GMO propaganda and like most activists in the GMO labeling movement, he is also broadly against the technology. In a December 2015 op-ed in the New York Times entitled, Are you eating Frankenfish? Colicchio warned readers that the newly approved GE fast-growing salmon could escape enclosed tanks and endanger native speciesclaims multiple US and Canadian regulators have reviewed and rejected as untrue. Colicchio has also come out in opposition to insect-resistant eggplant, grown with government developed seeds distributed free to farmers in Bangladesh, which has reduced the spraying of dangerous chemicals by 85 percent.

Why are celebrities getting so much traction in their campaign against GMOs? They are filling an information void left by the scientific and agricultural communities. Scientists are reluctant to engage the public, either out of trepidation or arrogance, convinced that science will win the day. Infighting has plagued the science communications effort as leaders dispute the best way to fight misinformation from people like Paltrow and Ruffalo.

Some want to take a submissive approach and others want to fight fire with fire. The agricultural community and companies that benefit from genetic engineering arent standing up to defend the technology, either.

While science and farming communicators struggle with how to best educate consumers and the media, organic executives and celebrities are defining the narrative on GMOs. This is not without serious ramifications if we turn away from genetically modified crops. Food prices will rise and farmers will be forced to use more insecticide and more toxic herbicides. Its wonderful to celebrate the performances of TV, movie and music celebrities, but their opinions on science issues are no more relevantnow than they were when they were waiting tables in Hollywood and Nashville looking for a break. Hit the mute button when they start opining on serious policy issues that have considerable consequences for vulnerable people around the world.

Julie Kelly is a cooking instructor, food writer, blogger and mother of two who lives in the Chicago area. In 2015, she got passionate about GMOs. Kelly is a contributing writer to the Wall Street Journal, National Review, Huffington Post and other media outlets.

The Genetic Literacy Project is a 501(c)(3) non profit dedicated to helping the public, journalists, policy makers and scientists better communicate the advances and ethical and technological challenges ushered in by the biotechnology and genetics revolution, addressing both human genetics and food and farming. We are one of two websites overseen by the Science Literacy Project; our sister site, the Epigenetics Literacy Project, addresses the challenges surrounding emerging data-rich technologies.

Read more:
When Celebrity And Science Collide: Hollywood And The Anti ... - Genetic Literacy Project

Read More...

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 – Business Wire (press release)

March 3rd, 2017 2:44 am

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2017. The AACR Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1 to April 5.

Full abstracts of the following presentations are available online at http://www.aacr.org:

Apr. 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4818 (Poster): Neratinib/fulvestrant but not fulvestrant alone maintain complete tumor responses after treatment with trastuzumab + paclitaxel of mice bearing ER+/HER2+ xenografts. L.J. Schwarz et al, Vanderbilt University Medical Center.

April 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4157 (Poster): Co-blockade of mTORC1, ERBB and estrogen receptor signaling pathways in endocrine resistant breast cancer: combating tumour plasticity. R. Ribas et al, Institute of Cancer Research.

April 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4038 (Poster): Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer. M. Zhao et al, MD Anderson Cancer Center.

April 5, 2017, 8:00 - 12:00 p.m. EDT Abstract 5167 (Poster): Stem-like colorectal cancer cell lines show response to the ERK1/2 inhibitor, SCH772984, alone and in combination with neratinib while the combination of MEK-162 and neratinib work to decrease tumor growth in inflammatory colorectal cancer subtypes. R. Pal et al, NSABP.

April 5, 2017, 8:00 - 12:00 p.m. EDT Abstract 5684 (Poster): NSABP FC-7 Correlative Study: HER2 amplification in circulating cell-free DNA (cfDNA) in metastatic colorectal cancer (mCRC) resistant to anti-EGFR therapy. S. Rim Kim et al, NSABP.

Full abstracts of the following presentations are expected to be available online March 31, 2017, after 4:00 p.m. EDT:

April 2, 2017, 12:45 - 3:00 p.m. EDT Abstract CT001 (Oral, Clinical Trials Plenary Session): Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study. D. Hyman et al, Memorial Sloan Kettering Cancer Center.

April 2, 2017, 3:00 - 5:00 p.m. EDT Abstract CT011 (Oral, Minisymposium): Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC). C. Ma et al, Washington University School of Medicine.

April 2, 2017, 3:00 - 5:00 p.m. EDT Abstract CT013 (Oral, Minisymposium): NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC). J. Abraham et al, NSABP.

April 3, 2017, 10:30 a.m. 12:45 p.m. EDT Abstract LB103 (Oral, Major Symposium): Landscape of Somatic ERBB2 Mutations - Findings from AACR GENIE and Comparison to Ongoing ERBB2 Mutant Basket Study. A. Schram et al, Memorial Sloan Kettering Cancer Center.

April 4, 2017, 1:00 - 5:00 p.m. EDT Abstract CT128 (Poster): Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial. E. Ibrahim et al, Beaver Medical Group LP.

About Puma Biotechnology:

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found atwww.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Visit link:
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 - Business Wire (press release)

Read More...

Rheumatoid arthritis drug a potential targeted therapy for aggressive cancer – FierceBiotech

March 3rd, 2017 2:44 am

A mutation in the tumor-suppressing genePTENcauses uncontrolled growth in several types of cancer. Mount Sinai researchers foundan approved rheumatoid arthritis drug that stops this growth in its tracks and could be a possible new treatment for aggressive cancers.

PTEN mutations occur in many cancers, including the brain cancer glioblastoma, as well as lung, breast and prostate cancers. They modify a metabolic pathway in tumors, which accelerates DNA production and leads to the unchecked growth of the cancer.

The Mount Sinai team, led by Ramon Parsons, M.D., Ph.D., discovered thatthe drug leflunomide inhibits an enzyme in the pathway, which damages the DNA the pathway produces. This ends up destroying PTEN-mutant cancer cells while sparing healthy cells, according to the statement. Sanofi markets leflunomide as Arava.

To test the drugs efficacy, the researchers transplanted human breast cancer cells into mice. Leflunomide drastically reduced the breast cancer tumors in the mice. The findings are published in Cancer Discovery.

A number of groups are studying PTEN to find new options for difficult-to-treat cancers. Earlier this year, Cold Spring Harbor scientists found that the proteinImportin-11protects the PTEN gene by transporting it into the nucleus of cells. They noticed that lung cancer patients with low levels of Importin-11 also lacked PTEN. Meanwhile, Ohio State researchers discovered that the enzyme PMRT5 blocked PTENs tumor-suppressing activity.

Mount Sinai's Parsonshopes to pit leflunomide against breast and colon cancer in a clinical trial. "Finding successful targeted therapies for cancer is a challenging but important goal in the face of insufficient treatment options," said Parsons in the statement. "Targeted therapies that are tumor-specific are much needed, and identifying changes based on specific tumor suppressor or oncogene alterations will facilitate this effort. Due to the high mutation rate of PTEN in cancer, the effects of PTEN could be at the heart of targeted therapy."

Original post:
Rheumatoid arthritis drug a potential targeted therapy for aggressive cancer - FierceBiotech

Read More...

New treatment option for difficult-to-treat rheumatoid arthritis patients – Medical Xpress

March 3rd, 2017 2:44 am

March 2, 2017 by Johannes Angerer A hand affected by rheumatoid arthritis. Credit: James Heilman, MD/Wikipedia

Between 3 and 5 percent of the population suffers from a form of inflammatory rheumatism. It affects approximately 250,000 to 400,000 people in Austria. Rheumatoid arthritis is one of the most common and also the most dangerous forms of this inflammatory rheumatic disease. Around 30 percent of patients achieve remission, described as successful control of symptoms, after just one or two years. However, despite frequent changes in treatment, many patients endure the active form of the disease on an ongoing basis. A multicentre, multinational study headed up by rheumatologist Daniel Aletaha of MedUni Vienna as principal investigator has now shown that a new drug (sirukumab) is a promising treatment option for these "refractory" patients. The study has now been published in The Lancet.

Today, doctors change treatments for rheumatoid arthritis very quickly if one treatment fails to effect any significant improvement in a patient. This means that many patients can be helped very quickly. On the other hand, there are patients who do not show any significant improvement even after the second or third biologic drug treatment typically with tumour necrosis factor (TNF) inhibitors. TNF is involved in systemic inflammation. The new drug now offers a promising option for such patients.

This is the result of one of the largest multicentre, international studies ever conducted into difficult-to-treat rheumatoid arthritis. It focuses on a new mechanism of action, an interleukin-6 cytokine blockade. In this treatment, the monoclonal antibody sirukumab directly inhibits the messenger substance IL-6, which, like TNF, is responsible for inflammatory processes in the joints.

"We were able to demonstrate this in one of the largest study populations to date, with around 900 patients in 35 countries. Despite having previously received treatments with biologic drugs, these patients still had a persistently active disease. Treatment options had been practically exhausted for many of these patients. However, even in this group of patients, treatment with sirukumab brought about a significant reduction in the inflammatory action of the disease," says Daniel Aletaha of MedUni Vienna's Department of Medicine III.

The efficacy and safety of sirukumab were tested in two different dosages (injections of 50 mg every four weeks or 100 mg every two weeks). The 100 mg dosage proved to be slightly more effective. "These results are very significant in the case of a progressive, inflammatory, musculoskeletal disease such as rheumatoid arthritis, especially for those patients who are resistant to treatment," says the MedUni Vienna expert. The drug could be approved very soon.

At the same time, the new findings with sirukumab could lead to new efficacy studies being instigated for other inflammatory diseases, such as other forms of arthritis or other inflammatory diseases, e.g. vasculitis. There may also be other indications in areas other than rheumatology.

Explore further: New assay may lead to a cure for debilitating inflammatory joint disease

More information: Daniel Aletaha et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study, The Lancet (2017). DOI: 10.1016/S0140-6736(17)30401-4

Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at ...

(HealthDay)A non-tumor necrosis factor (TNF)-targeted biologic is more effective than a second anti-TNF drug for treatment of rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug, according ...

A Mayo Clinic study is shedding light on why some rheumatoid arthritis patients respond poorly when treated with tumor necrosis factor inhibitors, part of a class of drugs called biologics. It comes down to proteins: specifically, ...

A well-known rheumatoid arthritis medication containing the active agent adalimumab, a therapeutic human monoclonal antibody, is also effective for treating non-infectious uveitis, a rare eye disease. This has now been discovered ...

The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents ...

Together with colleagues from the international rheumatic diseases research community, scientists of the Charit Universittsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis ...

A research team led by scientists from Brigham and Women's Hospital (BWH) has carefully scrutinized the immune cells from patients with rheumatoid arthritis, revealing a striking new subset of T-cells that collaborate with ...

Combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the disease's earliest stage, according to researchers at Washington University ...

About one million Americans each year undergo total knee or hip replacements, but complications bring as many as 1 in 12 back to the hospital and result in higher use of post-acute services within 90 days.

Using a novel approach for imaging the movement of immune cells in living animals, researchers from the Massachusetts General Hospital (MGH) Center for Immunology and Inflammatory Diseases (CIID) have identified what appear ...

Older adults who suffer from arthritis need to keep moving to be functionally independent. But in an examination of a goal that is daunting for most of this aging population, a new Northwestern Medicine study found that performing ...

(HealthDay)Everybody believes running can leave you sore and swollen, right? Well, a new study suggests running might actually reduce inflammation in joints.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
New treatment option for difficult-to-treat rheumatoid arthritis patients - Medical Xpress

Read More...

Depression increases the risk of developing psoriatic arthritis: Study – Bel Marra Health

March 3rd, 2017 2:44 am

Home Anti-Aging Arthritis Depression increases the risk of developing psoriatic arthritis: Study

Those with the skin disease psoriasis may be at an increased risk for developing psoriatic arthritis if they also suffer from depression. This link has been confirmed by a new study recently published in the Journal of Investigative Dermatology and asserts that depression can raise a psoriasis patients risk of developing psoriatic arthritis by as much as 37 percent.

The connection between depression and psoriatic arthritis is especially concerning, as the mental health condition is not uncommon in those living with the inflammatory skin disease.

Psoriasis causes red, itchy, and scaly patches to develop on the skin of patients that can sometimes be disfiguring and lead to negative thoughts about their appearance. While psoriatic arthritis can occur without the skin disorder, it most often accompanies it and causes joint pain, swelling, and has the potential to result in joint damage.

Previous research has linked major depressive disorder with an increased risk for systematic inflammation, meaning the mental condition can sometimes have physical manifestations as well. This systematic inflammation could increase the patients risk for developing psoriatic arthritis.

By analyzing data from over 70,000 psoriasis patients aged 25 and older, researchers were able to determine that those who had been or still were suffering from depression were at a much higher risk of developing psoriatic arthritis.

Depression has been linked to a number of chronic diseases as a factor that increases their risk of development, and this new research has revealed that psoriatic arthritis can be added to the list, at least in the case of those already diagnosed with psoriasis.

Related: Facts about psoriatic arthritis

Related Reading:

Home remedies to soothe your psoriasis

That itch! Get to know the symptoms and causes of psoriasis

http://www.webmd.com/arthritis/psoriatic-arthritis/news/20170224/can-depression-up-odds-for-arthritis-linked-to-psoriasis

Link:
Depression increases the risk of developing psoriatic arthritis: Study - Bel Marra Health

Read More...

Facing arthritis at a young age, Katie Dean turns to faith – The Simpsonian

March 3rd, 2017 2:44 am

by Madi Wilson, Features/Perspectives Editor March 2, 2017

Diagnosed with rheumatoid arthritis at age 11, sophomore Katie Deans childhood was different than most.

In 2008, Dean was playing basketball when she tripped and fell. Her left ankle quickly swelled up, making it extremely painful for her to walk on. She assumed it was a sprained ankle until her right hand started swelling up days later.

If you take a latex glove and blow it up, thats about the size [my right hand] was, Dean said. It was red and we decided that that is not good, so we went to the doctor.

Treating her swelling and redness as an infection, doctors soon realized they were wrong. Dean had developed more than just a swollen ankle and hand.

I began to get a rash around my waist, which they had never seen before, Dean said. So as a fifth-grader, thats kind of scary.

Dean was regularly in and out of the University of Iowa Childrens Hospital, and because her hand was extremely large, she had three or four different surgeries to extract pus.

Months later, doctors treated Dean with arthritis medicine, and it worked. They officially diagnosed her with RA and identified her rash as Sweets syndrome, a rare skin disease thats triggered by infections, illnesses or certain medications.

RA, an inflammatory disease in which the immune system attacks healthy joints and causes symptoms including pain, swelling, stiffness and loss of physical function, affected Deans ability to participate in sports.

I was in a lot of sports, she said. I was in basketball, volleyball and I did track. I continued to do those up until junior high because I had the mindset that I could do anything. But after, like, practices or games, I was always limping around, and I couldnt run. I realized that I couldnt do all of the things that I really wanted to do.

Although Deans experience was a physical setback, she didnt let her diagnosis negatively influence her academic efforts.

Im really school-focused, and so I knew that I could still do school no matter if I was in or out of the classroom. So it wasnt really a mental setback, but I did see myself as different for a really long time.

Deans experience was challenging, but there was one thing that helped her through it all: writing.

While I was sick I actually thought, you know, that God was punishing me for some reason, Dean said. I actually started writing about my condition and my faith, and I knew that I was obviously strong enough to get through it.

Since her diagnosis, Dean has written a few books titled A Step of Faith (2012), An Unforgettable Journey (2014), Healings, Hospitals, Happiness (2014) and is working on a novel called Bumps in the Road.

Through these novels, she hopes to help people with their tough experiences through forms of faith.

Dean also used prayer to guide her through her situation.

I guess what really helped was my mom, and I prayed every single day about it and every single night. And so that really had an impact on seeing God in a different way, she said.

Along with writing and prayer, Deans support system was, and still is, tremendous. Her parents were always by her side along with many of her friends who still ask how shes doing.

My friends were also very supportive, Dean said. They understand what I go through, and every time I see them they always ask, How are you doing? Is there anything that we need to do for you?

Deans arthritis is managed through her medication and a shot she takes every other week, but she occasionally has episodes of pain.

Every time I do have what I call flare, people are always aware and always try to help, she said.

One group thats made a huge impact on Deans life is Religious Life Community. After participating in a trip to Florida through RLC, she realized that God was calling her to be a minister.

Im really active in my home church, and so Ive always had that part of me, she said. Ive spoken in church a couple times, and I really enjoy speaking in front of people about God.

Majoring in religion with a double minor in theater and music, Deans plans are to go to seminary after she graduates. She hopes to use her experience to inspire others and teach them that faith can overcome any obstacle in life.

Read more:
Facing arthritis at a young age, Katie Dean turns to faith - The Simpsonian

Read More...

Keithley’s Korner: Big benefits from Stem Cell Therapy – Ruidoso News

March 3rd, 2017 2:43 am

Tim Keithley, Guest columnist 7:45 a.m. MT March 2, 2017

Tim Keithley(Photo: Courtesy)

Like a lot of folks who love to go skiing, play tennis, and enjoy the Ruidoso year-round beautiful weather, I became discouraged when my right knee went out climbing down a staircase recently.

I waited a few days figuring that it might heal like it always has done before. But this time the injury felt different and seemed to be getting worse.

Turns out you have a torn tendon in your right knee, Dr. Steven Rath of Fusion Medical Spa said on New Mexico in the Morning.

It obviously wasnt going to heal itself, so we had Tim come in and consider stem cell therapy, Dr. Rath said. It turns out that we were able to help his body heal itself without putting him through painful knee surgery.

Within a day after the procedure this week, the knee was sore from having the shots injected right into the tendon, but the regular pain had subsided. It made me a believer in the stem cell therapy Dr. Rath has been talking about on the radio for some time.

Heres a simple explanation of the procedure: Dr. Rath draws your own blood, then separates out the healing platelets through a spinning process, then injects those back into your body to the specific area that needs healing.

Stem cell therapy is nothing new, but its still considered an alternative form of treatment and an experiment, Dr. Rath said. Part of the reason why insurance companies dont cover the procedure has to do with the fact that medical companies prefer patients have surgery when it may not be necessary.

There may be patients out there who definitely need surgery, but providing this procedure has kept many of my patients from having to go under the knife.

Having had the procedure done on my knee this week, I can testify that it works and has given me a new hope that soon Ill be back on the slopes and the tennis court without having the ordeal of potential knee surgery.

Thus far in my practice, stem cell therapy has helped many people in your same situation, Dr. Rath said.

Tim Keithley is the host of the New Mexico in the Morning radio show Monday through Friday, 9 to 10 a.m., on KRUI 1490 AM, KWMW 105.1 FM and 99.1 FM or live streaming at mtdradio.com.

Read or Share this story: http://r-news.co/2lDmO8k

More here:
Keithley's Korner: Big benefits from Stem Cell Therapy - Ruidoso News

Read More...

International Stem Cell Corporation Announces Third Patient with Parkinson’s Disease in Phase I Clinical Trial – GlobeNewswire (press release)

March 2nd, 2017 1:54 am

February 28, 2017 08:30 ET | Source: International Stem Cell Corporation

CARLSBAD, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced the third patient in the clinical trial for Parkinson's Disease was successfully transplanted with ISC-hpNSCcells and is already discharged from the Royal Melbourne Hospital (RMH). The operation was successfully performed without complications by the team of the RMH neurosurgeons.

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO commented: "The third operation went according to plan and we are on track to dosing all of our clinical trial participants in 2017. We have enrolled the fourth patient and we expect to perform the surgery in March. No test article related adverse events have been recorded for any of the patients transplanted in 2016.

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC, intracranially transplanted into patients with moderate to severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSCwill be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

About Parkinson's disease

Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.

Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.

About ISC-hpNSC

International Stem Cell Corporation's proprietary ISC-hpNSCconsists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSCis a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC. ISC-hpNSCprovides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSCis safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSCmay have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of human pluripotent stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit:www.facebook.com/InternationalStemCellCorporationandwww.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected results and timing of clinical studies, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Related Articles

International Stem Cell Corporation

Carlsbad, California, UNITED STATES

International Stem Cell Corporation Logo

LOGO URL | Copy the link below

Formats available:

See more here:
International Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial - GlobeNewswire (press release)

Read More...

Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity – Medical Xpress

March 2nd, 2017 1:54 am

March 1, 2017 Neural progenitor cells (green) in the lateral ganglionic eminence (LGE), the region in the developing brain that produces the majority of adult neural stem cells. Credit: Sven Falk

Neurodegenerative diseases such as Alzheimer's or Parkinson's, but also strokes or other types of traumatic brain damage, result in the death of nerve cells in the brain. Since the mammalian brain is capable of replacing nerve cells only in certain restricted regions, such nerve-cell loss is in most cases permanent. Similarly, the capacity to form new nerve cells in the mature brain is limited to specific areas. The cells responsible for neurogenesis in the mature brain are called adult neural stem cells, but little is known about their developmental origins. Now an international research collaboration led by Magdalena Gtz, Professor of Physiological Genomics at LMU's Biomedical Center and Director of the Institute for Stem Cell Research at the Helmholtz Zentrum Munich, has demonstrated that the mode of division of stem cells has a profound influence on the numbers of adult neural stem cells formed during embryonic development.

The new findings appear in the journal Neuron.

Neural cells develop from progenitors called neural stem cells, which are produced in large numbers during embryonic development. However, in the mature mammalian brain, very few of these progenitors survive as so-called adult neural stem cells capable of generating new nerve cells. In order to determine what enables these cells to retain their stem-cell character into adulthood, Gtz and her colleagues took a closer look at neural stem cells in the developing mouse embryo called radial glia cells (RGCs). RGCs form long processes that span the apicobasal axis of the neuroepithelium and their nuclei come to lie close to the apical surface which faces a fluid-filled cavity known as the ventricle. When RGCs divide, some of the daughter cells again are RGCs, i.e. the RGC self-renews. These cells that retain the self-renewing capacity, a characteristic of stem cells, are the source of the adult neural stem cells found in a specific region of the developing brain called the lateral ganglionic eminence, which forms the lateral wall of the ventricle in the adult brain. The nerve cells derived from the adult neural stem cells subsequently migrate into the olfactory bulb, one of the regions in which new nerve cells are integrated in the mature brain.

"We have now shown that the orientation of the plane of division of embryonic progenitor cells has a major impact on the production of adult neural stem cells," Gtz says. The plane of cleavage during cell division determines which parts of the cytoplasm are inherited by the two daughter cells. Most of the RGCs in the lateral ganglionic eminence were found to divide along a plane that is approximately vertical (at an angle of 60-90) to the apical cell surface. However, when the researchers genetically randomized the orientation of the cleavage plane such that the frequency of oblique or horizontal divisions was increased the number of adult neural stem cells generated was significantly reduced. Hence the orientation of the cleavage plane of RGCs is a crucial factor that affects the number of adult stem cells. However, timing also plays a crucial role. Adult neural stem cells are produced only during a specific, temporally and regionally restricted phase in embryonic development. Genetic randomization of the cleavage plane progenitor cells in the post-natal mouse brain proved to have no effect on the number of adult stem cells.

The total number of adult neural stem cells produced is a crucial determinant of the brain's capacity for repair and regeneration, because each of these cells can generate only a limited number of new nerve cells. "With a better understanding of how the formation of adult neural stem cells is regulated, we could look for ways of ensuring that other embryonic neural stem cells maintain this capacity, and perhaps even persuade other cell types to do so. Our new results represent an important step toward this goal," says Sven Falk, first author of the new study. The researchers hope that their findings will open up new approaches to the therapy of neurodegenerative diseases.

Explore further: Specific roles of adult neural stem cells may be determined before birth

More information: Sven Falk et al. Time-Specific Effects of Spindle Positioning on Embryonic Progenitor Pool Composition and Adult Neural Stem Cell Seeding, Neuron (2017). DOI: 10.1016/j.neuron.2017.02.009

Adult neural stem cells, which are commonly thought of as having the ability to develop into many type of brain cells, are in reality pre-programmed before birth to make very specific types of neurons, at least in mice, according ...

Stem cells in the brain can produce neurons and are consequently seen as a hope for treatment. A team of researchers from the Helmholtz Zentrum Mnchen and Ludwig-Maximilians-Universitt Mnchen (LMU) has now discovered ...

Prof. Fiona Doetsch's research team at the Biozentrum, University of Basel, has discovered that the choroid plexus, a largely ignored structure in the brain that produces the cerebrospinal fluid, is an important regulator ...

Blood vessels play a vital role in stem cell reproduction, enabling the brain to grow and develop in the womb, reveals new UCL research in mice.

A wireless arm patch may be a promising new treatment for migraine headaches, researchers report.

Scientists have used a unique computational technique that sifts through big data to identify a subset of concussion patients with normal brain scans, who may deteriorate months after diagnosis and develop confusion, personality ...

(HealthDay)Multiple sclerosis (MS) is more likely to progress to advanced disease among patients who suffer from fatigue and limited use of their legs, new research suggests.

How does consciousness arise? Researchers suspect that the answer to this question lies in the connections between neurons. Unfortunately, however, little is known about the wiring of the brain. This is due also to a problem ...

(Medical Xpress)A team of researchers with the Allen Institute for Brain Science led by Christof Koch gave a presentation recently at the Brain Research through Advancing Innovative Neurotechnologies meeting outlining ...

Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bioassay grown on multi-electrode arrays capable of detecting the biological activity of Clostridium botulinum ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity - Medical Xpress

Read More...

Stem cells make potential drug side effects personal – New Atlas

March 2nd, 2017 1:54 am

Researchers in Singapore have developed a wayto use patients'stem cells to see whether acancerdrug is safe for them(Credit: Institute of Bioengineering and Nanotechnology)

In a promising development that strengthens the case for personalized cancer care, scientists in Singapore have demonstrated the possibility of predicting the potential for an individual to have adverse side effects to different drugs by first testing them on stem cells made from the patient's own blood.

For doctors, prescribing cancer drugs is often a hit-or-miss affair. Even though a therapy has been approved by a regulatory body, there's still a chance someone could have a bad reaction and develop severe side effects, such as liver failure. Such cases are termed idiosyncratic, as opposed to intrinsic, which can be predicted and therefore avoided. As the name suggests, with idiosyncratic drug-induced liver injury (DILI) it is difficult to predict a drug's side effects on an individual patient in advance, which could lead to hospitalization and even death.

Pazopanib is a drug commonly prescribed for advanced kidney cancer. However, like many cancer therapies, it doesn't work for everyone and has been known to cause liver damage in patients who react badly to it. In the study, researchers at the Institute of Bioengineering and Nanotechnology (IBN) and the National Cancer Centre Singapore (NCCS) used induced pluripotent stem cells (iPSCs) adult cells that have been genetically reprogrammed into an embryonic cell-like state to create liver cells from the blood of five kidney cancer patients, three of whom were known to have adverse reactions to the cancer drug. The goal was to find out if they could reproduce adverse reactions to pazopanib in these cells.

When these newly created liver cells were exposed to the drug, the researchers found that not only were the results similar to post-treatment data derived from liver biopsies, they were also able to gain a better understanding of how the drug caused liver damage, which was previously unknown to doctors. This is the first time that a study has demonstrated the ability of genetically matched iPSCs to model drug-induced idiosyncratic side effects, which may result from predisposing genetic factors that an individual patient might have. What the results make clear is that idiosyncratic DILI has multiple causative factors and cannot be attributed to a single risk factor.

"Our hypothesis was that liver cells made from the individual's blood might show similar sensitivity or resistance to pazopanib," says study author Min-Han Tan, a medical oncologist. "This study is the first proof-of-concept that our approach can predict drug-induced liver damage for an individual. Importantly, we were able to figure out how the drug works from the way they react to the liver cells, which was unknown to doctors, even after many years of using this drug."

Among the findings was the identification of the role altered iron metabolism could play in pazopanib-induced liver injury. NCCS consultant Ravindran Kanesvaran believes understanding the mechanism of this particular side effect of the drug could lead to ways to overcome it.

While the study's small sample size might bring with it statistical limitations, the researchers, who are currently planning formal clinical trials, believe these findings could provide impetus for using patient-specific stem cells to screen for idiosyncratic drug reactions, especially since there is currently no suitable test for these cases.

Further studies on drugs that affect other organs are in the pipeline, and the researchers say in the future it might be possible to predict a patient's reaction to a drug by screening personalized stem cells comprising a range of liver, lung, kidney and heart cells.

Apart from benefitting patients, such a procedure could also help keep promising therapies on the market. Presently, phase III clinical trials (i.e. the stage that assesses the effectiveness of a new therapy) involve patient groups comprising between 300 and 3,000 people. And because they are so rare, it is easy for cases of idioscyncratic DILI to slip under the radar during these trials. As the study's authors note, this results in "considerable morbidity, mortality, treatment dose attenuation and interruption," which often leads to drugs being pulled off the market, depriving patients who do not have such reactions of what could be a promising treatment for them.

"Currently, new drugs are tested for toxicity using generic liver cells, which cannot model patient-specific reaction," says team leader and principal research scientist Hanry Yu. "By personalizing liver cells from the blood of individual patients, we can help doctors to prescribe safer and more effective therapies."

The paper was published in Scientific Reports.

See the original post here:
Stem cells make potential drug side effects personal - New Atlas

Read More...

Creo Medical Group joins European stem-cell cancer project … – DIGITALLOOK

March 2nd, 2017 1:54 am

Medical device company Creo Medical Group said it was taking part in a European programme researching a stem-cell cancer treatment for brain tumours.

The AIM-listed company is to join the Semiconductor-based Ultrawideband Micromanipulation of Cancer Stem Cells (SUMCASTEC) H2020 FET open research programme, led by the XLIM Research Institute at the University of Limoges in France.

Creo will be one of six European partners in a consortium of neurologists, microbiologists and engineers, who are aiming to develop a "micro-optofluidic lab-on-chip platform that deploys semi-conductor technology to neutralize cancer stem cells with electromagnetic waves".

The consortium was awarded a 4m (3.4m) grant, and 530,000 of which will be allocated to Creo, which lead on the development of the cell neutralisation aspect of the programme with a view to potentially commercialise the lab-on-chip platform.

Creo said that certain aspects of the project are closely related to the work it is already doing for the treatment of lung tumours.

SUMCASTEC is based on the isolation and neutralisation of cancer cells associated with some of the most aggressive brain tumours, specifically Glioblastoma Multiforme and Medulloblastoma.

Brain cancers are a leading cause of death in Europe, as according to the World Health Organisation 57,000 new cases and 45,000 deaths were reported in Europe in 2012.

Chris Hancock, chief technology officer of Creo, said: "This grant recognises the potential of Creo Medical's innovative ablation technology and its potential application in new and challenging fields. This new system has the potential to provide a new treatment option for some of the most aggressive brain tumours."

Arnaud Pothier, main project leader and senior researcher at Limoges University, added: "Creo's development expertise and growing commercial infrastructure makes them an ideal consortium partner to bring the lab-on-chip into human use and then to market."

Shares in Creo Medical Group were up 0.77% to 92.2p at 1524 GMT.

Follow this link:
Creo Medical Group joins European stem-cell cancer project ... - DIGITALLOOK

Read More...

New Retinal Device May Give Hope To The Blind – CBS Chicago

March 2nd, 2017 1:53 am

March 1, 2017 10:08 PM By Marissa Bailey

(CBS) A blind man can see light for the first time in 20 years, all thanks to a revolutionary device being researched right here at the University of Illinois-Chicago.

CBS 2s Marissa Bailey explains how it could change the lives of the blind.

This is no regular eye doctors appointment.

This is Bob Selbys first check-up since Dr. Jennifer Lim at UIC implanted the groundbreaking retinal device called the Argus II.

Ive been legally blind my whole life, really, Selby says.

The 55-year-old was born with Retinitis Pigmentosa. He was diagnosed in his 20s and completely blind by 35.

The part of the retina that doesnt work is the part of the retina that gathers the light. The photoreceptors are dead but the inner retina works, Dr. Lim explains.

Selbys device was implanted in October and thenturned on in November. Thats when he saw light flashes for the first time in more than 20 years.

Now he can see edge and contrast effects and can pick people out, but before he didnt know where they were unless they would say something, Lim says.

Heres how the device works: The lens on Selbys glasses transmits an image through a video processor box. It wirelessly sends instructions to the implant on Selbys eye. Those messages stimulate Selbys retina to send signals along the optic nerve to his brain, which allows him to see.

Within minutes of turning on the device, Selby was navigating unfamiliar hallways by himself.

Wow! Ive never been so happy to see a wall before, he said that day.

Selby calls the technology a game-changer.

For patients, its huge.To be able to see light and then not only to see the light but to have the light mean something, Lim adds.

Selby practices with his new found sight a couple of hours a day.

He says if he can see light flashes now, this may be the beginning of the end for blindness.

Imagine what they could do in five to 10 years, he says.

Selby is one of only 60 people in the world with this FDA-approved retinal implant. UIC is one of 13 sites in the U.S. where its being used.

The Argus II is now being studied in Europe for people with macular degeneration.

Marissa Bailey is the weekend anchor of the CBS 2 Chicago morning newscasts and a general assignment reporter for the station. Marissa joined the station in March 2012 as a reporter and was promoted to anchor the stations Saturday and Sunday...

Link:
New Retinal Device May Give Hope To The Blind - CBS Chicago

Read More...

Beware Of This ‘Thief Of Sight’ That Can Gradually Cause Blindness – malaysiandigest.com

March 2nd, 2017 1:53 am

Details Published on Thursday, 02 March 2017 08:32 Written by Thorsten Marquardt

Glaucoma, the silent thief of sight, is a group of diseases caused by damage to the optic nerve in the eye.

Without any warning signs or symptoms it will slowly take away the affected persons eye sight and can even cause blindness if not treated appropriately.

Tanaletchimy Rajaratnam, 63, felt completely healthy and had no symptoms at the time she was diagnosed with high eye pressure during a routine eye screening in the UK.

With high eye pressure being the number one cause for glaucoma, she decided to start the treatment right away.

Taking the risk seriously, going for regular checkups and starting with the treatment early enough helped keeping the diseases progress at bay.

This is the reason why today, 10 years after she was diagnosed with glaucoma, her eye sight has not been significantly affected.

Without early detection and swift action, this could have played out very differently.

Another patients son, Mr Wong, told MalaysianDigest, at the Tun Hussein Onn National Eye Hospital that his 75 year old father had been affected by glaucoma for a long time without even noticing it.

Only after the disease had already severely damaged his eyes and even started to cause pain, he finally consulted a doctor.

Without appropriate treatment, he is now at risk of going blind.

Before being diagnosed with the disease, like most people, both patients werent even aware of its existence. Like many other glaucoma patients in Malaysia, Wong andTanaletchimy accounts of the onset of the disease highlights the invisible nature of this condition until it is too late.

The Malaysia Glaucoma Society had produced the following public announcement about this disease a few years back to create awareness of this 'silent thief of sight'.

The World Glaucoma Week held in March each year takes place on 12 to 18 March 2017 and to help raise awareness, we have decided to highlight this often 'invisible' illness and look at a local eye hospital's role in helping glaucoma patients.

The Silent Thief Of Sight

If the optic nerve that connects the eye to the brain is too damaged, it will not be able to send an accurate and complete picture to the brain causing reduced eye sight.

This results in people having blurry vision and a restricted field of view or missing objects in their view.

Glaucoma usually comes without any symptoms and often stays undetected for a long time.

Not always, but very often, glaucoma is caused by high eye pressure damaging the optic nerves.

To be more specific, glaucoma usually develops when the production of an eye fluid called aqueous humour either increases or fails to drain properly.

This causes the pressure in the eye to rise which can damage the fibres in the optic nerve resulting in interruptions to the transmission of visual messages to the brain.

Eye drops are used to reduce the eye pressure and keep it stable to prevent further damage to the nerves.

Eye pressure is the main cause for glaucoma, but not required for its development.

People with normal eye pressure can still be affected, while people with high eye pressure are more likely to be at risk but dont necessarily develop the disease.

It is estimated that half of the people affected by glaucoma do not know that they have it, which is a serious problem because if left undetected and untreated it can lead to blindness.

According to the World Health Organization, Glaucoma is the second most common cause of blindness worldwide and it is estimated that 4.5 million persons globally are blind due to glaucoma.

If left untreated, most types of glaucoma progress (without warning nor obvious symptoms to the patient) towards gradually worsening visual damage and may lead to blindness, states the World Glaucoma Association.

Since there is no cure, the damage caused to the optic nerves and the reduced eye sight are irreversible, therefore it is important to detect it early.

There is no cure for glaucoma as yet, and vision loss is irreversible. However medication or surgery (conventional or laser) can halt or slow-down any further vision loss. Therefore, early detection is essential to limiting visual impairment and preventing the progression towards severe visual handicap or blindness, states the World Glaucoma Association.

Everybody Is At Risk Of Glaucoma

Datuk Dr. Linda Teoh, a full time consultant ophthalmologist and glaucoma specialist at the Tun Hussein Onn National Eye Hospital (THONEH), told MalaysianDigest that everybody can be affected by glaucoma.

There are certain risk factors, like for example high eye pressure and a family history, but the disease can affect anyone.

It is not just about the eye pressure. The eye pressure might be normal but the person can still develop glaucoma. There can also be people with high eye pressure but no glaucoma. Too many people look only at the eye pressure, she said.

People with high eye pressure are at a much higher risk of getting glaucoma and it is generally assumed that people with a family history of glaucoma already have a 1 in 4 chance of developing the disease.

There are, however, many other factors that come into play.

Everybody is potentially at risk of developing glaucoma, but there are certain risk factors that increase the likelihood.

People above the age of 60, people with diabetes, people who have used steroids for a long period of time and people with physical eye injuries are also at a higher risk.

Some ethnicities are more prone to the disease than others.

The Glaucoma Research Foundation found that African Americans are more likely to be affected by glaucoma than Caucasians.

The ingredients of certain weight loss appetite suppressant pills are also linked to an increased risk.

In Malaysia around 1.8 percent of the population is affected by glaucoma and, according to surveys, only 21 percent of the population are even aware of the disease.

Since glaucoma is very unpredictable, can affect anyone and comes without warning, routine eye checkups, measuring eye pressure and conducting visual field tests are crucial in detecting and treating the disease early enough to avoid major irreversible damage to the eye sight.

Education And Cooperation Between Doctor And Patient Are The Key To A Successful Treatment

When it comes to treating glaucoma, it is very important that the patient and the doctor are on the same page.

Since glaucoma is a disease that continuously gets worse while causing irreversible damage, regular checkups and adjustments to the treatment are very important.

In order to keep the disease from progressing, it is required to keep the eye pressure low and stable.

Datuk Dr. Linda Teoh, a full time consultant ophthalmologist and glaucoma specialist at the Tun Hussein Onn National Eye Hospital (THONEH)Glaucoma is actually a group of diseases causing damage to the optic nerve of the eye. By controlling the eye pressure, the drops can slow down the progress of glaucoma, Dr. Linda explained.

I think what is important is education. Patients should know the nature of the disease and understand how it progresses.

Despite the aggressive nature of the disease and lack of cure, it is possible to prevent the loss of eye sight through appropriate treatment.

This, however, can be costly, time consuming and requires the patients to actively take an interest in informing themselves about the disease and be compliant with their medication.

Dr. Linda thinks that a lack of education and knowledge about the disease leads many patients to be neglectful and hamper the effectiveness of the treatment.

They feel there is no improvement in spike of treatment. They fail to understand the nature of the disease. Then they blame the doctor if they dont get better. They always want to improve, but what they dont understand is that Glaucoma cannot be improved; its progress can only be slowed down. What they need is education, she said.

In order to successfully treat the disease and prevent it from progressing, patients have to go for regular checkups, use the prescribed medicine correctly, meet doctors regularly to adjust the treatment based on changing conditions and undergo surgery (to control the eye pressure) if the necessity arises.

The drops used to reduce the eye pressure, for example, have to be adjusted regularly depending on whether the eye pressure are effectively controlled in order to avoid fluctuations that damage the optic nerve further.

Dr. Linda opined that patients who are either too uninformed and ignorant about the disease or dont trust the doctors are more likely to fail at properly treating the disease.

Tanaletchimy, who managed to slow down the progress of the disease by being very proactive and engaged with her doctors also sees cooperation between doctors and patients as the most important factor.

Just listen to what the specialists have to say. They are the experts. You must have confidence in the doctor and just follow what the doctor suggests, she said.

According to Dr. Linda, education, cooperation with the doctor, early detection and early treatment are the most important factors in successfully treating glaucoma.

In conjunction with the World Glaucoma Week 2017 starting from March 12, the Tun Hussein Onn National Eye Hospital (THONEH) will be hosting an open day on 22 March 2017 (Wednesday).

There will also be a presentation ceremony and a series of programmes including an eye health talk open to the public. For further information, contact THONEH at 603-7718 1588 or email This email address is being protected from spambots. You need JavaScript enabled to view it..

-mD

Originally posted here:
Beware Of This 'Thief Of Sight' That Can Gradually Cause Blindness - malaysiandigest.com

Read More...

‘Treasure map’ identifies first genetic clues to form of blindness – Blue Mountains Gazette

March 2nd, 2017 1:53 am

27 Feb 2017, 6:11 p.m.

Researchers have identified genetic clues which could reveal a person's risk of going blind.

Tom Doumani thought something was up when he started having trouble reading street signs while driving. Letters seemed to be missing and, if the street name was an unfamiliar one, he had no way of guessing what it might be.

It was enough to prompt him to go and get his eyes tested. However the results showed his long distance vision was fine.

Unconvinced all was as it should be, he mentioned it to his GP who referred him to an eye specialist. This time the tests picked it up. Dr Doumani had the rare and rather awkwardly named Macular Telangiectasia type 2.

Like many rare conditions, little is known about what causes "MacTel 2", which in scientific circles is known as idiopathic juxtafoveal telangiectasia. Idiopathic meaning "of unknown cause".

However that may have changed, thanks to research led by Melbourne scientists which has found "a treasure map" revealing the location of the genetic triggers behind this little-understood form of blindness.

Outlined in the journal Nature Genetics, it is the first clue as to what causes MacTel 2, an incurable and untreatable degenerative disease which affects people from age 40 upwards.

The condition is characterised by an abnormal growth of blood vessels in the macula. Patients lose their central vision and tasks such as driving and reading can become impossible.

The international study was led by Walter and Eliza Hall Institute of Medical Research scientists Melanie Bahlo and Thomas Scerri.

The research team, including scientists in New York and London, analysed more than 6 million genetic markers in the genome of patients with the condition and compared them to those without.

Among the 476 people diagnosed with MacTel 2, genetic similarities were found in five key regions of the genome.

Curiously four of the five regions are associated with a person's metabolism. Those with MacTel 2 recorded lower levels of the basic amino acids glycine and serine.

"That was a bit of a surprise to say the least," Professor Bahlo said.

The fifth region identified, in what Professor Bahlo has described as "our treasure map", is tied to the size of retinal blood vessels.

"This is the first time we have been able to say with certainty that this is a genetic condition," she said. "And the map tells us where to 'keep digging' in order to discover the specific genes implicated in MacTel 2."

Identifying the specific genes would lead to improved diagnostic testing for the disease which is notoriously difficult to identify and also developing ways to prevent or stop its progression.

Diagnosed in 2012 at the age of 61, retired corporate banker Tom Doumaniwas among theMelbourne participants, sourced through Centre for Eye Research Australia. Heknows that while he may not benefit directly from participating in the study, he is contributing to the global search for a cause or cure.

"To help advance the knowledge, that's what appealed to me in taking part," he said. "I had no hesitation in participating."

The story 'Treasure map' identifies first genetic clues to form of blindness first appeared on The Sydney Morning Herald.

See more here:
'Treasure map' identifies first genetic clues to form of blindness - Blue Mountains Gazette

Read More...

Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima – Yahoo Finance

March 2nd, 2017 1:53 am

HAMILTON, N.J., March 1, 2017 /PRNewswire/ -- Genesis Biotechnology Group (GBG), a consortium of an integrated group of biotechnology and research companies, announced that it has expanded its drug development services by the acquisition of PharmOptima.

PharmOptima, a preclinical Contract Research Organization (CRO) company, joins Invivotek and Venenum Biodesign in the existing drug development segment of GBG. This acquisition expands GBG's catalogue of available services, while providing the same high quality service each company's clients have grown to expect. Effective with this acquisition, GBG will provide new and existing customers with the added value of a single point-of-contact for the efficient development and coordination of their unique preclinical drug development program.

According to Dr. Eli Mordechai, GBG's CEO, "This partnership brings together highly complementary services of three companies creating a dynamic and efficient enterprise that will enable clients to have access to a comprehensive portfolio of bio-analytical and in vivo services in multiple therapeutic areas." This spirit of collaboration was supported by PharmOptima's CEO, Steven Weber, who stated, "PharmOptima is excited to become a part of the GBG consortium that will have the synergistic effect of expanding both the breadth and depth of expertise in advancing the drug development activities of our clients and partners."

About GBG

GBG is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. Through the consolidation of research activities, and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG will be better positioned to create and sustain complex research platforms in drug discovery and the design of surrogate biomarkers for chronic diseases.

About PharmOptima

Since 2003, PharmOptima has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development. PharmOptima's in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology.It provides liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines.Its biochemistry expertise allows them to assess the role of biomarkers in numerous disease models. PharmOptima's biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression. Its expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.

About Invivotek

Invivotek offers both custom and standard preclinical services for drug discovery and development programs for their clients. Services offered by Invivotek include studies in animal models and bioassays to test compounds related to immunology and inflammation, oncology, metabolic and cardiovascular diseases.Invivotek's in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as by functional assays with primary cell cultures. These assays provide tools to study the mechanisms of action of various test therapeutics or potential target genes and to explore biomarkers for drug efficacy. Invivotek's experience across multiple therapeutic areas and its efficient project management, positions the company as a leading provider of preclinical in vivo services.

About Venenum Biodesign

Venenum Biodesign (Venenum) focuses on the identification of potentially therapeutic compounds starting with ultra-high throughput screening (UHTS) against their proprietary 5.5 million ECLiPS compound collection. Compounds identified by UHTS are advanced into preclinical drug candidates using in-house medicinal chemistry, crystallography and molecular modeling. Venenum's drug discovery biology capabilities are supported by expertise in in vitro andcell-based assay development, protein expression and purification, and assay reagent generation. Venenum has extensive experience working in a wide variety of therapeutic areas with conventional target classes, such as G protein-coupled receptors (GPCRs), enzymes, nuclear hormone receptors (NHRs), as well as with protein-protein or protein-DNA interactions.

Read More

Go here to see the original:
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima - Yahoo Finance

Read More...

Page 1,082«..1020..1,0811,0821,0831,084..1,0901,100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick